Physician profile
Sydney King
NPI 1568472983
$3,311.16
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,315 · 2020: $437 · 2021: $257 · 2022: $223 · 2023: $54.79 · 2024: $24.69.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $79.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $79.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,361.02 | 2019 | |
| Boston Scientific Corporation | $558.77 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $333.29 | 2019-2022 | |
| Amgen INC. | $328.26 | 2019-2022 | |
| Opsens INC. | $164.18 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $160.28 | 2020-2021 | |
| Siemens Medical Solutions USA, INC. | $78.14 | 2019 | |
| Novartis Pharmaceuticals Corporation | $77.87 | 2019-2023 | |
| Cardiovascular Systems INC. | $69.59 | 2019-2020 | |
| Kestra Medical Technology Services, INC. | $50.43 | 2022-2023 | Assure Wcd |
| Sanofi-Aventis U.S. LLC | $46.38 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $29.50 | 2020-2022 | |
| Cvrx, INC. | $24.69 | 2024 | Barostim Neo System |
| Biotronik INC. | $14.46 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.30 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sydney King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.